This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Gentium Appoints Biologix FZCo As Exclusive Distributor Of Defibrotide In The Middle East And North Africa

VILLA GUARDIA (COMO), Italy, Oct. 4, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) announced today the appointment of Biologix FZCo as the exclusive distributor of Defibrotide in the Middle East and North Africa (MENA).

Under the terms of the agreement, which is valid for 10 years, Biologix will be responsible for managing named-patient requests and obtaining price and reimbursement approvals in the MENA region. Following regulatory approval to market Defibrotide, if any, Biologix will be responsible for sales, marketing and local medical affairs activities in this region.

"We are pleased to have established a long-term relationship with Biologix for the distribution of Defibrotide in the Middle East and North Africa, consistent with our overall commercial strategy to partner with strong local distributors," said Adrian Haigh, Senior Vice President of Commercial Operations at Gentium. "Local distribution partners with strong experience in hematology and well-established local relationships, such as Biologix, help to facilitate access to Defibrotide."

"We look forward to working with Gentium and are pleased with the addition of Defibrotide to our specialty distribution portfolio. The partnership with Gentium will allow us to provide MENA patients access to this potentially life-saving treatment," said Selim Ghorayeb, Managing Partner at Biologix.

About Gentium

Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) and Orphan Medicinal Product Designation by the European Medicines Agency both to treat and to prevent veno-occlusive disease (VOD) and Fast Track Designation by the U.S. FDA to treat VOD. 

The Gentium S.p.A. logo is available at

About Biologix

Biologix FZCo, a company established under the laws of UAE in 2003, provides for the distribution and marketing of biotech products in the MENA region. Equipped with a logistics hub based in Dubai Airport Free Zone and supported by a qualified workforce, it offers effective Regulatory, Medical, Marketing, Sales and Distribution support to its partners with a direct and adequate presence in 17 countries of the Middle East and North Africa including Saudi Arabia, UAE, Kuwait, Bahrain, Oman, Qatar, Yemen, Iran, Iraq, Lebanon, Syria, Jordan, Egypt, Libya, Tunisia, Algeria, and Morocco. Biologix' main therapeutic focuses are Oncology-Hematology, Central Nervous System and Rare Diseases.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs